Sort by
Refine Your Search
-
Listed
-
Country
-
Employer
-
Field
-
at the intersection of biology, and medicine? We’re seeking a talented Scientist to join our dynamic team! Our mission is to develop novel PET imaging agents for widely metastatic cancers and to develop novel
-
, or erroneous data, Data cleaning and generation, Development of enhanced loss functions and information-theoretic methods for optimized data analysis, Machine learning-based image segmentation of tomographic
-
. - Have skills in image analysis (segmentation, cell tracking, spatio-temporal quantification) and quantitative analysis of biological data. - Familiarity with classical approaches in protein biochemistry
-
during pathological conditions. 2. Neonatal seizures and epilepsy 3. GABAA receptor physiology. We approach these research areas with electrophysiological and imaging. The Postdoctoral researcher will be
-
Job Description Apply now Job Title: Postdoctoral Fellow PhD Division: Neurology Work Arrangement: Onsite only Location: Houston, TX Salary Range: Hiring up to $62,232 FLSA Status: Exempt Work
-
Job Description Apply now Job Title: Postdoctoral Fellow PhD Division: Neurology Work Arrangement: Onsite only Location: Houston, TX Salary Range: Hiring up to $62,232 FLSA Status: Exempt Work
-
– Full Time DEPARTMENT/DIVISION: Division of Hepatic, Kidney, and Transplantation Pathology, Department of Pathology, University of Pittsburgh, of the University of Pittsburgh Medical Center
-
(the Harvard Kenneth C. Griffin Graduate School of Arts and Sciences, founded in 1872), Harvard Athletics and the Division of Continuing Education. The 40 academic departments and 30+ centers of the FAS support
-
research program focused on spatial immuno-oncology, utilizing cutting-edge technologies (e.g., spatial transcriptomics, spatial proteomics, imaging mass cytometry) to study the tumor microenvironment
-
, biology, and medicine? We’re seeking a talented Scientist to join our dynamic team! Our mission is to develop novel PET imaging agents for widely metastatic cancers and to develop novel radioligand